Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Senzime

4,77 SEK

-1,14 %

Mindre end 1K følgere

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-1,14 %
-15,12 %
-26,16 %
-7,92 %
-13,27 %
-16,32 %
-58,80 %
-78,02 %
-19,62 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Læs mere
Markedsværdi
749,92 mio. SEK
Aktieomsætning
606,96 t SEK
Omsætning
58,48 mio.
EBIT %
-212,12 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
18.2
2026

Årsrapport '25

22.4
2026

Delårsrapport Q1'26

19.5
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse19.11.2025, 07.09

BioStock: Video from Senzime's presentation at BioStock Life Science Summit 2025

Senzime
Pressemeddelelse11.11.2025, 12.00

Senzime to Present at Redeye and BioStock Investor Conferences

Senzime
Pressemeddelelse3.11.2025, 13.45

Nomination Committee for Senzime Annual General Meeting 2026

Senzime

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse30.10.2025, 13.49

Redeye: Senzime (Q3 Review) - In the right direction

Senzime
Selskabsmeddelelse29.10.2025, 07.30

SENZIME Q3 2025: STRONG GROWTH AND CLEAR STEPS TOWARDS PROFITABILITY

Senzime
Pressemeddelelse23.10.2025, 09.00

Invitation to presentations of Senzime’s third quarter 2025 report

Senzime
Pressemeddelelse8.10.2025, 11.00

Senzime launches EMGINE, the next-generation software suite advancing neuromuscular monitoring

Senzime
Pressemeddelelse3.10.2025, 12.30

Senzime welcomes new European pediatric guidelines recommending EMG-based neuromuscular monitoring

Senzime
Pressemeddelelse17.9.2025, 11.15

Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center

Senzime
Pressemeddelelse12.9.2025, 08.00

Senzime to Present at Pareto Securities’ 16th Annual Healthcare Conference

Senzime
Pressemeddelelse12.9.2025, 07.00

Senzime launches integration with Mindray patient monitors

Senzime
Pressemeddelelse9.9.2025, 09.00

Senzime welcomes new Japanese guidelines on neuromuscular monitoring

Senzime
Pressemeddelelse8.9.2025, 11.15

Senzime to Present at the European Growth Virtual Investor Conference on September 11

Senzime
Pressemeddelelse4.9.2025, 14.30

Extensive Clinical and Competitive Evaluation Leads Major California University Hospital System to Standardize on Senzime’s TetraGraph System

Senzime
Pressemeddelelse4.9.2025, 09.06

Redeye: Redeye Initiates Coverage of Senzime

Senzime
Pressemeddelelse5.8.2025, 09.00

Senzime Secures TetraGraph Installations Across All Sites of World-Leading US Hospital System

Senzime
Selskabsmeddelelse31.7.2025, 13.00

New number of shares and votes in Senzime AB (publ)

Senzime
Pressemeddelelse23.7.2025, 08.15

Senzime’s TetraGraph System Receives Regulatory Approval in Mexico

Senzime
Pressemeddelelse22.7.2025, 15.19

DNB Carnegie Access: Senzime: Scalability set to become more apparent in H2 – Q2 review

Senzime
Pressemeddelelse18.7.2025, 11.00

DNB Carnegie Access: Senzime: Recording from earnings call Q2 (25)

Senzime
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.